{"id":29511,"date":"2014-08-26T10:30:49","date_gmt":"2014-08-26T14:30:49","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=29511"},"modified":"2014-08-26T10:30:49","modified_gmt":"2014-08-26T14:30:49","slug":"kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511","title":{"rendered":"Kite Pharma Inc (NASDAQ:KITE) Plans To File Investigational New Drug Application"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 08\/26\/2014 (wallstreetpr) \u2013 <strong>Kite Pharma Inc (NASDAQ:KITE)<\/strong> welcomes the good <a href=\"http:\/\/online.wsj.com\/articles\/kite-pharmas-cancer-drug-shows-positive-results-in-study-1409012354\" target=\"_blank\">news<\/a> of positive results coming from its clinical trial of cancer treatment. The shares surged more than 20% on the news in after-hours trading. Also, Kite Pharma has plans to file a new drug application for the clinical trial of KTE-C19 drug. It is a treatment drug for the patients suffering from large B-cell lymphoma who have not responded to the two or more lines of therapy.<\/p>\n<p style=\"text-align: justify;\"><strong>The study<\/strong><\/p>\n<p style=\"text-align: justify;\">Kite Pharma Inc (NASDAQ:KITE) treated fifteen patients suffering from aggressive non-Hodgkin&#8217;s lymphoma with its cancer drug in Phase 1-2a clinical trial. In the study, eight patients were in complete remission while the four patients were in partial remission. The results of the study were published in the Journal of Clinical Oncology.<\/p>\n<p style=\"text-align: justify;\">The clinical trial was conducted by the National Cancer Institute and was self-funded by Kite. Out of the fifteen patients, thirteen patient\u2019s results were evaluable. The group consists of two patients who were re-treated in the trial. Kite Pharma Inc (NASDAQ:KITE) was formed in 2009, and it primarily develops the treatment therapy that uses the patient\u2019s immune system for treating cancer.<\/p>\n<p style=\"text-align: justify;\"><strong>The management view<\/strong><\/p>\n<p style=\"text-align: justify;\">David Chang, Executive Vice President, Research &amp; Development, and CMO of Kite Pharma Inc (NASDAQ:KITE), said that Kite and the NCI together have conducted studies to find the effective treatments for solid tumors and blood cancers. The results of the studies and the response rate are encouraging. Also, the remission durability of the disease was noteworthy.<\/p>\n<p style=\"text-align: justify;\">Chang further said that there is much potential in its anti-CD19-CAR T cell approach for treating B cell malignancies. The results are especially significant as they successfully treated the patients suffering from relapsed, refractory lymphomas. The success of the Phase 1-2a clinical trial has encouraged Kite to file an IND in the last quarter of the year. It will be Phase 1-2 clinical trial of KTE-C19 in patients with DLBCL. The patient enrollment for a clinical trial will start in the first half of 2015.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 08\/26\/2014 (wallstreetpr) \u2013 Kite Pharma Inc (NASDAQ:KITE) welcomes the good news of positive results coming from its clinical trial of cancer treatment. The [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":29523,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[8383,8382,7552,7553],"stock_ticker":[],"class_list":["post-29511","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-david-chang","tag-kite-pharma-inc","tag-kite-pharma-inc-nasdaqkite","tag-nasdaqkite","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kite Pharma Inc (NASDAQ:KITE) Plans To File Investigational New Drug Application - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kite Pharma Inc (NASDAQ:KITE) Plans To File Investigational New Drug Application - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 08\/26\/2014 (wallstreetpr) \u2013 Kite Pharma Inc (NASDAQ:KITE) welcomes the good news of positive results coming from its clinical trial of cancer treatment. The [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-26T14:30:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/KITE.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"225\" \/>\n\t<meta property=\"og:image:height\" content=\"225\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Steve Hackney\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Hackney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511\"},\"author\":{\"name\":\"Steve Hackney\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\"},\"headline\":\"Kite Pharma Inc (NASDAQ:KITE) Plans To File Investigational New Drug Application\",\"datePublished\":\"2014-08-26T14:30:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511\"},\"wordCount\":353,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/KITE.jpg\",\"keywords\":[\"David Chang\",\"Kite Pharma Inc\",\"Kite Pharma Inc (NASDAQ:KITE)\",\"NASDAQ:KITE\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511\",\"name\":\"Kite Pharma Inc (NASDAQ:KITE) Plans To File Investigational New Drug Application - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/KITE.jpg\",\"datePublished\":\"2014-08-26T14:30:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/KITE.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/KITE.jpg\",\"width\":225,\"height\":225},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kite Pharma Inc (NASDAQ:KITE) Plans To File Investigational New Drug Application\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\",\"name\":\"Steve Hackney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"caption\":\"Steve Hackney\"},\"description\":\"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kite Pharma Inc (NASDAQ:KITE) Plans To File Investigational New Drug Application - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511","og_locale":"en_US","og_type":"article","og_title":"Kite Pharma Inc (NASDAQ:KITE) Plans To File Investigational New Drug Application - Wall Street PR","og_description":"Boston, MA 08\/26\/2014 (wallstreetpr) \u2013 Kite Pharma Inc (NASDAQ:KITE) welcomes the good news of positive results coming from its clinical trial of cancer treatment. The [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-08-26T14:30:49+00:00","og_image":[{"width":225,"height":225,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/KITE.jpg","type":"image\/jpeg"}],"author":"Steve Hackney","twitter_misc":{"Written by":"Steve Hackney","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511"},"author":{"name":"Steve Hackney","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867"},"headline":"Kite Pharma Inc (NASDAQ:KITE) Plans To File Investigational New Drug Application","datePublished":"2014-08-26T14:30:49+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511"},"wordCount":353,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/KITE.jpg","keywords":["David Chang","Kite Pharma Inc","Kite Pharma Inc (NASDAQ:KITE)","NASDAQ:KITE"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511","url":"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511","name":"Kite Pharma Inc (NASDAQ:KITE) Plans To File Investigational New Drug Application - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/KITE.jpg","datePublished":"2014-08-26T14:30:49+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/KITE.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/08\/KITE.jpg","width":225,"height":225},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/kite-pharma-inc-nasdaqkite-plans-to-file-investigational-new-drug-application-29511#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Kite Pharma Inc (NASDAQ:KITE) Plans To File Investigational New Drug Application"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867","name":"Steve Hackney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","caption":"Steve Hackney"},"description":"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/29511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=29511"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/29511\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/29523"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=29511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=29511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=29511"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=29511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}